Enzyme Replacement Therapy Medicines
Supply of Enzyme Replacement Therapy Medicines (e-g) to NHS Scotland: - NP92624(e) Velaglucerase alfa 400units powder for solution for infusion vials 1 vial (VPRIV®) - NP92624(f) Idursulfase 6mg/3ml solution for infusion vials 1 vial (Elaprase®) - NP92624(g) Agalsidase alfa 3.5mg/3.5ml solution for infusion vials 1 vial (Replagal®)
Buyer
The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
Value
£6,079,596
Published
15 Aug 2024
Closes
15 Aug 2024
Procurement details
Source
Pcs
Region
Scotland
Procurement method
Limited
Category
Goods
Contract starts
Not provided
Contract ends
Not provided
CPV classifications
33600000
Pharmaceutical products
Lots
Lot 1 Enzyme Replacement Therapy Medicines
£6,079,596
The Framework Agreement is for the supply of Enzyme Replacement Therapy Medicines (e-g: VPRIV®/ Elaprase®/ Replagal®) to NHS Scotland. The Authority has awarded this framework as a Single supplier framework agreement to one (1) Framework Participant.
Delivery: Scotland
Documents
Unlock document linkEnzyme Replacement Therapy Medicines
Not provided
Supply of Enzyme Replacement Therapy Medicines (e-g) to NHS Scotland: - NP92624(e) Velaglucerase alfa 400units powder for solution for infusion vials 1 vial (VPRIV®) - NP92624(f) Idursulfase 6mg/3ml solution for infusion vials 1 vial (Elapr...
Award notice · Web page
Contains public sector information licensed under the Open Government Licence v3.0.